Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymalin

Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique

Quick Stats
Studies 202
Trials 37
Score 2
1996 pubmed

[Evaluation of the effectiveness of immunomodulators in the treatment of patients with postoperative suppurative-septic complications].

Bulava. G V GV; Nikulina. V P VP

Key Findings

  • Thymalin increased T‑cell counts only when combined with immunoglobulins or immune plasma
  • T‑activin boosted both T‑ and B‑cell numbers regardless of vaccine co‑administration
  • Myelopid raised B‑cell numbers and IgM/IgG levels after 14 days; clinical benefits were strongest when immunomodulators were paired with vaccines, but immune markers didn’t fully explain the improvements

Practical Outcomes

  • For self‑experimenters, thymalin might only show immune‑cell benefits when taken with antibody‑rich supplements, but the evidence comes from postoperative septic patients, not healthy volunteers. There’s no clear dosage or protocol for routine use, so treat it as experimental and consider safer, better‑studied options for immune support.

Summary

The study tested thymalin and other immune‑boosting drugs in patients who had serious infections after surgery. Thymalin only raised T‑cell numbers when it was given together with antibody‑rich treatments like immunoglobulins or plasma, while other drugs worked more on their own. The results were seen in very sick patients, not healthy people, so the findings are only a hint, not a ready‑to‑use plan for everyday biohackers.

Abstract

The influence of immunoactive medicines on the cell immunity have been studied. There were differences in reaction to T-activin and Thymalin between various patients with septic postoperative complications. Thymalin stimulated T-cells while acting with immunoglobulins or immune plasmas only. T-activin led to the increase in the number of T-lymphocytes and B-lymphocytes independently of it's cooperation with the vaccines. The stimulating effect of myelopid demonstrated itself by increase in the number of B-lymphocytes and immunoglobulins M and G after 14 days of treatment. The positive clinical effect was more impressive when immunomodulators were used in combinations with the vaccines; still it did not correlate completely with the dynamics of the cell immunity parameters.

Study Information

Provider

pubmed

Year

1996